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Abstract
Background: The terms affective dysregulation (AD) and irritability describe transdiagnostic dimensions and are
characterized by an excessive reactivity to negative emotional stimuli with an affective (anger) and a behavioral
component (aggression). Due to early onset, high prevalence and persistence, as well as developmental
comorbidity, AD in childhood is one of the most psychosocially impairing and cost-intensive mental health
conditions. AD is especially prevalent in children in the youth welfare service. Despite continuous research, there
remains a substantial need for diagnostic approaches and optimization of individualized treatment strategies in
order to improve outcomes and reduce the subjective and economic burden.
Methods: The ADOPT (Affective Dysregulation – Optimizing Prevention and Treatment) Consortium integrates
internationally established, highly experienced and interdisciplinary research groups. The work program
encompasses (a) epidemiology, including prevalence of symptoms and disorders, (b) development and evaluation
of screening and assessment tools, (c) stepped care approaches for clinically useful personalized medicine, (d)
evaluation of an easily accessible and cost-effective online intervention as indicated prevention (treatment effects,
moderation/mediation analysis), and (e) evaluation of an intensive personalized modular outpatient treatment in a
cohort of children with AD who live with their parents and in a cohort of children with AD who live in out-of-
home care (treatment effects, moderation/mediation analysis).
Discussion: The results will lead to significant recommendations for improving treatment within routine clinical
care in two cohorts of children with AD and coexisting conditions, especially oppositional-defiant disorder, conduct
disorder and disruptive mood dysregulation disorder.
Trial registration: Trial registration ADOPT Online: German Clinical Trials Register (DRKS) DRKS00014963. Registered
27 June 2018.
Trial registration ADOPT Treatment: German Clinical Trials Register (DRKS) DRKS00013317. Registered 27 September 2018.
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Background
Affective dysregulation (AD) or irritability is characterized
by excessive reactivity to negative emotional stimuli with an
affective (anger) and a behavioral component (aggression).
Accordingly, individuals with AD are overly angry or
aggressive in response to provocations. Depending on the
defining concept of AD, prevalence rates among children
and adolescents range from 0.8 to 6.6% [1, 2]. AD or irrit-
ability is a criterion for many diagnoses in children in the
5th edition of the Diagnostic and Statistical Manual of
Mental Disorders (DSM-5) [3] and the 10th revision of the
International Classification of Diseases (ICD-10) [4], includ-
ing mood and anxiety disorders, attention-deficit/hyper-
activity disorders (ADHD), conduct disorders (CD), and
oppositional defiant disorders (ODD). Given the overlap of
AD symptoms with the criteria for these diagnoses, it is not
surprising that high rates of AD are found in children with
ODD/CD, ADHD, anxiety disorders, and mood disorders
[5], as well as in children with attachment disorders and
posttraumatic stress disorders. Conversely, in children with
AD, high rates of these comorbid conditions can be found.
AD features are most prominent in ODD [6, 7].
AD is not a diagnostic entity in the DSM-5 or ICD-10,
but fits well within the framework of the National Insti-
tute of Mental Health Research Domain Criteria (RdoC)
initiative [8], which investigates dimensional constructs
that cut across multiple diagnoses and can be examined
on multiple levels. The current RdoC include the con-
struct of frustrative non-reward within the negative emo-
tionality domain that encompasses AD [9]. The recently
published 11th revision of the International Classification
of Diseases (ICD-11) defines AD as a diagnostic additive to
ODD, which can now be diagnosed as ODD with or with-
out AD [10].
There is broad evidence that at least 30–50% of children
living in institutional care and foster care (out-of-home
care; OHC) have mental health problems. Indeed, several
studies have shown that up to 90% of these children fulfill
criteria for at least one psychiatric diagnosis [11–13]. Exter-
nalizing behavior and diagnoses, including AD symptoms,
have been found to be especially prevalent in children living
in OHC. Mental disorders often lead to multiple place-
ments and to a discontinuation of youth welfare service
interventions, culminating in poorer outcomes later in life
[14]. An analysis employing the definition of the Child Be-
havior Checklist Dysregulation Profile (CBCL-DP) reported
that the prevalence of AD symptoms in 10–14-year-old
children in OHC in Switzerland lay at 11.1% for girls and
13.5% for boys [15].
In both preventive and psychotherapeutic contexts, be-
havioral parent management training (PMT) is regarded
as an evidence-based treatment to decrease child exter-
nalizing behavior problems [16], including symptoms of
AD. As shown by various meta-analyses, cognitive-be-
havioral PMT is effective in reducing child externalizing
behavior problems in general [17], in children with
ADHD [18], and in children with ODD and CD [16].
Analyses of mediating processes in PMT have attributed
the positive treatment effects to the reduction of dys-
functional parenting [19] as well as to increases in posi-
tive parenting [20] and improvements in parent-child
relationships [21].
Effects of PMT vary based on characteristics of the
family and the child [22]. An example of family factors
that are reported to undermine the effectiveness of PMT
is family adversity, such as low socioeconomic status or
single parenthood. Previously reported child factors pre-
dicting PMT outcome include the nature and severity of
symptoms [23] as well as child gender [24]. The two
meta-analyses of PMT reached different conclusions
with respect to the moderation of interindividual differ-
ences in treatment outcome: While [22] found that
economic disadvantage was the most salient moderator,
favoring children with less family adversity, the more
recent review by [17] did not find moderating effects
either for symptom severity or for socioeconomic status.
Despite clear evidence supporting the efficacy and cost-
effectiveness of PMT, interventions can be hard to access
for families living in rural areas or exhibiting psychosocial
adversities [17]. Practical factors which hinder parents’ at-
tendance include lack of local availability, transportation, or
childcare [16]. Book- or Internet-based, telephone-assisted
self-help PMT interventions seem to be effective and easy-
to-access alternatives to face-to-face PMT [25–27]. In their
meta-analysis, [25] estimated the pooled standard mean dif-
ference of 11 trials of self-directed parenting interventions
with no face-to-face therapist input. The examined inter-
ventions mostly comprised book- or video-based self-help
programs, and three out of the 11 programs combined
books with online tools. The authors reported large effect
sizes (M = 1.01; 95% CI = 0.7–1.24) for parent-reported
change in child problem behavior. However, the effects did
not hold (SMD = 0.15) when observed child behavior was
considered. Moreover, for all outcomes, the effect sizes
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decreased after the removal of interventions that
involved regular therapist contact via telephone or
Internet, suggesting that this had at least some medi-
ating effect. In a systematic review of 11 studies, [27]
identified nine different digital delivery methods (e.g.,
Internet, television, DVD), six of which used the Inter-
net as the primary method. The average proportion of
digitally delivered intervention completion lay at
78.3%, far outperforming the attendance rates of face-
to-face PMT [27].
Our own research group in Cologne has conducted various
randomized controlled trials (RCTs) on book-based and tele-
phone-assisted self-administered PMT. One year after the
intervention, positive treatment effects on child externalizing
behavior problems were maintained and the number of chil-
dren with externalizing behavior within the clinical range
was decreased [28, 29]. A comparison between a behavioral
and a nondirective guided self-help parent intervention in a
clinical sample of children with externalizing disorders
suggested that ODD, but not ADHD symptoms, showed
greater decreases in the behavioral intervention group than
in the nondirective group [30]. An analysis of mediating pro-
cesses attributed this differential treatment effect to a change
in parents’ dysfunctional attributions (less hostile intentions)
[31], implying that this aspect should be covered in PMT.
Cognitive-behavioral PMT can thus be regarded as an
evidence-based treatment to reduce child disruptive
behavior across various populations, subgroups within
populations, and delivery settings. It is also effective when
delivered in self-administered, Internet-based formats.
However, little is known about the effectiveness of similar
parenting interventions in relation to child emotional
problems like irritability [17, 32]. So far, PMT interven-
tions have focused on the behavioral but not the affective
component of AD. Preliminary evidence suggests that in
order to meet the needs of parents with highly irritable
children, regular PMT should be augmented with compo-
nents focusing on emotion regulation [33]. For instance,
[34] found that the presence of high levels of externalizing
symptoms predicted reduced efforts by parents to engage
in emotion regulation coaching with their child. This sug-
gests that there might be an especially harmful interplay
between child temperamental and behavioral characteris-
tics and parenting behavior in children with AD with
additional externalizing problems. Parents of children with
AD therefore need to be especially trained in promoting
their child’s emotion regulation. As parenting a child with
AD can be emotionally challenging, and negative affect
makes hostile and coercive reactions of parents more
likely [35], parents’ own emotion regulation capacities
should be enhanced as well. The model of mindful parent-
ing might be a helpful framework to support emotional
awareness and regulation of parent and child by increasing
parents’ full attention and nonjudgmental acceptance of
the child, and by supporting self-regulation in the parent-
ing relationship [36]. Recent findings suggest that mindful
parenting increases parents’ responsiveness [37] and regu-
lation of negative affect [38]. Heightened parental mind-
fulness has been found to lead to a decrease in parental
stress and child behavior problems [39, 40].
To the best of our knowledge, there are no previous or
ongoing studies evaluating extended self-help PMT for
children with AD, which cover child and parent emotion
regulation in addition to regular PMT topics. As severely
affected children with AD often live in families suffering
from multiple adversities, such specialized treatments
should address the specific needs of this population of
parents. Easy-to-assess Internet-based interventions seem
to be especially promising for highly burdened parents.
Besides PMT, cognitive behavior therapy (CBT) delivered
as (child-centered) psychotherapy has also been shown to
be effective for children with externalizing disorders,
ADHD, and ODD/CD [16, 41, 42]. We identified four
meta-analyses on the effects of psychosocial interventions
for children with AD/anger [41, 43–45]. Sukhodolsky et al.
[41] identified 21 published and 19 unpublished reports on
(patient-based) CBT for anger-related problems in children
and adolescents and calculated an overall mean effect size
of Cohen’s d = 0.67 (anger d = 0.72; aggression d = 0.63).
The differential effects of skills training, problem solving,
affective education, and multimodal interventions were
variable, although generally also in the medium range. A
meta-analysis including 60 studies found that school-based
anger management interventions were effective for out-
comes including anger, aggression, and loss of self-control
(overall effect sizes: d = 0.27 [43], d = 0.31 [44]). Another
meta-analysis of anger management training interventions
reported an overall moderate effect size of d = 0.61,
although this study was limited only to students with spe-
cial educational needs [45]. Effects of classroom-based and
teacher-involved interventions are also documented for pa-
tients with aggressive behavior (ODD/CD) and for ADHD.
Universal prevention was found to be effective in reducing
aggressive behavior in a meta-analysis conducted by the
National Institute for Health and Care Excellence (four in-
cluded studies; d = 0.43) [16].
Currently, several studies are planned or underway, which
aim to investigate the efficacy of interventions to reduce
anger, emotional dysregulation or irritability in children using
dialectical behavior therapy [NCT01299740], an interactive
biofeedback video game to regulate and gain emotional con-
trol [NCT01551732], or CBT [NCT01965184].
Most of the studies reported in the meta-analyses and
all of the ongoing trials consist of child-based treatments
that use standard group format programs and no per-
sonalized approach. This is also the case for the transdiag-
nostic approach to CBT for anger/irritability and aggression,
which combines interventions that aim at (a) regulating
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excessive anger, (b) learning social problem-solving strat-
egies, and (c) developing social skills alternatives to aggres-
sive behaviors [32, 46]. Group-based interventions are less
expensive, but may be less effective than individual treat-
ment approaches [47, 48].
Additionally, most traditional evidence-based CBT
programs focus on one disorder (or a small cluster of
related disorders), making it difficult for clinicians to ad-
dress heterogeneous caseloads, client comorbidities, and
changes in clinical presentation during therapy. Training
for each single-focus therapy can be time-consuming
and costly, and research participants in RCTs are typic-
ally treated for one disorder (whereas in clinical practice,
comorbidity is common).
Due to the diversity of symptoms of AD and associ-
ated disorders, a more flexible modular approach to
therapy for children is needed. Clinicians should be
guided by an evidence-based algorithm to tailor treat-
ment to each individual’s characteristics and needs. This
is especially true for high-risk populations like children
in OHC, who show high rates of adverse childhood
experiences, which is a strong predictor of psychopath-
ology. Psychotherapeutic approaches should comprise
modules that can be organized in a flexible manner.
Moreover, these modules should be based on cognitive-
behavioral and skills-based approaches for which meta-
analyses have shown the best evidence of effectiveness
for these disorders associated with AD, anger, and irrit-
ability. Furthermore, efforts should be undertaken to
identify frequently used common elements of evidence-
based practice for children.
Personalized individual modular treatment approaches
are rare [49], because individualized treatment packages
address specific deficits, for instance in anger control.
One of the few empirically tested personalized modular
approaches is the Modular Approach to Therapy for
Children with Anxiety, Depression, Trauma, or Conduct
Problems (MATCH-ADTC), which targets youth who
have any one or any combination of these problems
[50]. An RCT (n = 174) found that MATCH-ADTC was
more effective than standard (single-focus) evidence-
based therapies and usual care, with effect sizes of 0.59
to 0.71 for primary outcome variables [51]. Our own
research indicates that personalized modular CBT of the
patient improves ODD symptoms (including irritability)
and aggressive behavior [48, 52], and personalized
modular parent training improves ODD symptoms in
children with ADHD [53].
Evidence-based interventions to improve mental
health are particularly lacking for children living in
OHC, who have high rates of adverse childhood experi-
ences [54]. According to the German 13th Child and
Youth Report and a statement from the German govern-
ment, effective trauma-sensitive interventions are required
in this population [55]. Their needs are under-addressed
in both the youth welfare system and the health care
system. Therefore, an early intervention approach using
evidence-based CBT interventions to reduce AD symp-
toms is urgently needed, and has not yet been investigated.
Given the variability and complexity of the clinical picture
of AD in combination with comorbid conditions, a modu-
lar approach with a stepped care design is necessary,
which tailors evidence-based interventions to fit patient
needs.
Most previous studies used a group-based standardized
treatment approach, both in parent-based interventions
and in child-based cognitive-behavioral interventions.
Only a small number of studies have combined the effect-
ive components of child-based, parent-based, and teacher-
based interventions. Assessments of individual modular
approaches are rare. The only personalized modular
approaches either have a broader scope and include chil-
dren with internalizing symptoms (like MATCH-ADTC)
[50] or focus on specific disorders such as ADHD or
ODD/CD [48, 53]. The efficacy of an intensive personal-
ized modular approach including modules on CBT and
PMT in comparison to treatment as usual (TAU) has not
been evaluated [42, 49]. The effects on specific measures
of AD and moderating as well as mediating factors are
largely unknown.
Almost none of the studies published to date, or
which are currently being processed, assessed the ef-
fects of an intervention within a stepped care approach
(except 53). Symptoms of AD seem to vary broadly and
differ in intensity. Thus, a stepped care approach that
includes interventions with increasing intensity could
meet the individual needs of patients and families that
arise from different forms of AD.
ADOPT Online, ADOPT Treatment and ADOPT Institu-
tion are all part of the research consortium ADOPT
(Affective Dysregulation – Optimizing Prevention and
Treatment; https://www.adopt-studie.de). The goals of the
umbrella project are to (a) investigate the epidemiology of
AD including prevalence of symptoms and disorders, and
biological and psychosocial risk and protective factors
(ADOPT Epidemiology; ADOPT Neurobiology); (b) develop
and evaluate screening and assessment tools (ADOPT
Epidemiology; ADOPT Treatment); and (c) develop and
evaluate treatment approaches for clinically useful personal-
ized medicine in two cohorts of children with AD (ADOPT
Online; ADOPT Treatment; ADOPT Institution; see de-
tailed description below).
The primary objective of ADOPT Online is to assess the
overall efficacy of a PMT program that can be accessed
over the Internet (Online Parent Self-Help of Affective
Dysregulation and coexisting disorders; ADOPT Online).
In general, self-help or online PMT have proven to be
effective in reducing child behavior problems. However,
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they might only be capable of reaching a subpopulation of
parents [56], e.g., those who are better educated, less
burdened, or whose children are less affected. Self-help in-
terventions can thus serve as a time- and cost-effective
first step of intervention that can reduce symptoms in a
subpopulation [25, 49].
In the framework of a stepped care approach, the pri-
mary objective of ADOPT Treatment is to assess the over-
all efficacy of a personalized modular outpatient treatment
of AD and coexisting disorders (Therapy for Optimizing
Affective Regulation in children; THOPAS) in children
with substantial residual symptoms of AD after parents
have received Internet-based PMT (in ADOPT Online).
The primary objective of ADOPT Institution is to as-
sess the overall efficacy of THOPAS in 8–12-year-old
children living in OHC. These children are expected to
have higher rates of AD than children who live with
their natural parents. It is assumed that the treatment
effects on AD in children in OHC may differ from the
effects on children living with their parents, due to a
higher symptom load and more adverse childhood expe-
riences in the former group. Furthermore, professional
educational staff are already involved in institutional
care. Online guidance for effective parenting cannot be
considered as an appropriate intervention, since the staff
of the youth welfare service will already possess know-
ledge about positive parenting. Therefore, there was a
sound rationale for a specific study design for this popu-
lation, which provides direct, intensive treatment.
ADOPT Treatment and ADOPT Institution thus in-
tend to fill some of the aforementioned research gaps by
assessing the effects of THOPAS, either in a sample of
children who live with their parents or in a sample of
children living in OHC. Treatment strategies for mul-
tiple problems are organized into self-contained modules
that can be used multiple times or not at all, and can be
combined as needed; clinical decision-making flowcharts
give guidance about which modules to use and when to
use them for a particular patient [49]. Moreover, this in-
tensive personalized intervention will be applied within a
stepped care approach only in those cases in which a less
intensive and less expensive self-help online intervention
has proven to be insufficiently effective (see ADOPT
Online).
In all three ADOPT subprojects, the following princi-
pal research questions will be addressed:
(1) What is the overall efficacy of ADOPT Online
and of THOPAS (ADOPT Treatment and
ADOPT Institution) on AD and comorbid
conditions, functional impairment and
psychological well-being in comparison to TAU
in children (living with their parents or in OHC)
aged 8;0 to 12;11? What is the clinical
significance of the symptom change in terms of
normalization rates (in comparison to a control
group of participants without AD, defined at T1)
or reliable changes (RCI) [57]?
(2) How feasible is ADOPT Online and THOPAS and
how satisfied are parents/caregivers with the
intervention?
(3) Can specific psychopathological profiles be
identified (e.g., AD with high ADHD compared to
AD with low ADHD) that moderate/predict
treatment outcome?
(4) Which other moderators/predictors (e.g., gender,
age, parental mental health, adverse childhood
experiences) can be identified to predict treatment
outcome?
(5) Do the theoretically expected treatment
mechanisms work?
(6) What is the stability of the treatment outcome?
Additionally, the following research question will be
addressed in ADOPT Treatment and ADOPT
Institution:
(7) Can specific combinations of treatment modules be
identified (e.g. anger control training plus parent/
caregiver management training to reduce
dysfunctional parenting/caregiving; trauma therapy
to reduce trauma-specific symptoms) that predict
treatment outcome?
(8) Do children in OHC respond to treatment similarly
to children who live with their natural parents, or
can specific moderators of treatment response be
identified?
Furthermore, the following research questions will
be addressed in the other two ADOPT subprojects
(ADOPT Epidemiology and ADOPT Neurobiology),
which are not described comprehensively in the
present manuscript:
(9) What are the prevalence rates of AD in a
community sample and what are the comorbidity
rates in children with AD? (ADOPT Epidemiology)
(10)What are the psychosocial risk and protective
factors for AD and comorbid conditions in children
with AD, and how are AD and comorbid conditions
associated with well-being in children? (ADOPT
Epidemiology)
(11)What (neuronal) alterations of affective processing,
reward processing, cognitive control and attentional
functions can be identified in children with AD?
(ADOPT Neurobiology)
(12)What are the neuropsychological and/or
neurobiological predictors of response to
personalized psychotherapeutic treatment in
children with AD? (ADOPT Neurobiology)
(13)What are the relations between neurobiological
markers, neuropsychological measures, real-life
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behavior, retrospective parental ratings and
self-ratings of AD? (ADOPT Neurobiology)
Methods
Trial design
Figure 1 shows the overall design of the whole ADOPT
consortium. Sample recruitment in the community cohort
for ADOPT Online and ADOPT Treatment will be exe-
cuted by another ADOPT subproject (ADOPT Epidemi-
ology) and the initial screening will be performed in a
community sample. Sample recruitment in the outpatient
sample in ADOPT Online and ADOPT Treatment will be
performed by the study centers. The screening for AD in
ADOPT Institution will take place in children who live in
OHC.
Children will be selected for inclusion via a screening
instrument (Diagnostic Tool for Affective Dysregulation
in Children – Screening Questionnaire; DADYS-Screen)
[Görtz-Dorten et al., 2018, unpublished manuscript;
Otto et al., 2018, unpublished manuscript] which will be
developed by ADOPT Epidemiology. In addition, chil-
dren who show symptoms of AD according to clinical
judgment (outpatient sample) will also be included.
ADOPT Epidemiology will draw a community sample to
screen for children with AD. In total, data of N = 13,000
children aged 8 to 12 years will be collected across four
German Cities (Cologne, Dresden, Mannheim, Ulm).
The participants will be recruited through the residents’
registration offices of the four cities. In order to account
for an estimated dropout rate of 70–75%, the contact
details of 78,000 children will be requested from the
Fig. 1 Study design of the ADOPT consortium including ADOPT Epidemiology, ADOPT Online, ADOPT Treatment, ADOPT Institution as
well as ADOPT Neurobiology. Percentages indicate expected proportions of children with or without affective dysregulation. Dotted
boxes indicate subsamples used in ADOPT Neurobiology. T1 to T4 = assessment points; R = randomisation; AD = affective dysregulation;
ONLINE = web-based parent training; TAU = treatment as usual; TREATMENT = individualized cognitive behavioural psychotherapy of
child, parents, teachers; n = planned/estimated sample size. 1 Patients / Families can choose between continuation of TAU and
participation in Online
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registration offices. Based on screening data of the
ADOPT project, groups of children with high vs. low
AD will be defined using a cut-off which will be deter-
mined by means of a statistical case definition (10th
percentile). Additionally, n = 100 cases without AD will
be randomly drawn from the community sample and
asked about their willingness for ongoing participation
in the ADOPT study (No AD control group). The
ADOPT Epidemiology study office will inform the study
centers (see section “Study Setting”) about screening-
positive cases as well as participants of the control
group. In the outpatient sample, children will be
enrolled by clinicians. The study centers will invite the
participants and their parents to further participate in
the study from T1 onwards.
At T1, symptoms of AD will be more intensively evaluated
by clinicians’ ratings based on parent interviews conducted
with the outcome measure for AD (Diagnostic Tool for
Affective Dysregulation in Children – Parent Interview;
DADYS-PI) (Görtz-Dorten et al., 2018, unpublished manu-
script), which will be developed in ADOPT Epidemiology in
cooperation with ADOPT Treatment. Exclusion criteria
(intelligence quotient < 80; mental disorder other than
comorbid conditions is the primary disorder and the main
cause of AD (e.g., autism spectrum disorder); current or
planned intensive behavioral therapy (ADOPT Online)/in-
tensive psychotherapy or PMT (ADOPT Treatment/
ADOPT Institution) on a weekly/biweekly basis) will also be
assessed at T1/T2 (ADOPT Treatment), along with the resi-
dence of the child (ADOPT Online/ADOPT Treatment:
with natural or adoptive parents; ADOPT Institution: resi-
dential care or foster care). Additionally, two healthy control
groups (No AD; in ADOPT Online/ADOPT Treatment and
in ADOPT Institution) will be identified via the screening
and will be pursued from T1-T4 (ADOPT Online/ADOPT
Treatment) and from T1-T3 (ADOPT Institution).
In ADOPT Online, children selected from the commu-
nity sample and from the outpatient sample of the study
centers will be randomized to TAU or ADOPT Online.
Children will be reassessed after parents have had access
to ADOPT Online for 3months (T2). Families of the
community cohort randomized to TAU will gain access to
ADOPT Online after T2. Families of the outpatient sam-
ple randomized to TAU will be offered the choice between
continuing TAU and participating in the online interven-
tion (ADOPT Online) after T2. From T3 to T4, ADOPT
Online will also pursue those children who were in the No
AD group from the beginning as well as those who
showed no residual AD at T2. For detailed information
see Additional file 1: Trial registration ADOPT Online.
In ADOPT Treatment, children with substantial re-
sidual symptoms of AD after ADOPT Online, as rated
by the clinician on the outcome measure for AD based
on parent interview (DADYS-PI), will be included in
ADOPT Treatment. The patients will be randomized to
TAU or the psychotherapy intervention, which will com-
prise a modular, individual behavioral approach based
on THOPAS [Görtz-Dorten & Döpfner, 2018, unpub-
lished manuscript]. For detailed information see Add-
itional file 2: Trial registration ADOPT Treatment.
In ADOPT Institution, a total of n = 750 children in
OHC will be screened via a short screening instrument for
caregivers (DADYS-Screen) (Görtz-Dorten et al., 2018,
unpublished manuscript; Otto et al., 2018, unpublished
manuscript) at T0. Children with AD as rated by the clin-
ician on the outcome measure for AD (DADYS-PI) based
on parent interview will be included in ADOPT Institution.
The patients will be randomized to TAU or the psychother-
apy intervention with THOPAS. For detailed information
see Additional file 3: Trial registration ADOPT Institution.
Study setting
ADOPT Online and ADOPT Treatment are multisite trials
with five study centers located in four cities in Germany
(Cologne, Dresden, Mannheim, Ulm). If required, additional
centers will be included. ADOPT Institution is a multisite
trial with six study centers located in five cities in Germany
(Cologne, Dresden, Mannheim, Ulm, Neuruppin). The
coordinating center for ADOPT Online is the Department
of Special Education at the Faculty of Human Sciences at
the University of Cologne. The coordinating center for
ADOPT Treatment is the Department of Child and Adoles-
cent Psychiatry, Psychosomatics and Psychotherapy, Medical
Faculty at the University of Cologne. The coordinating cen-
ter for ADOPT Institution is the Department of Child and
Adolescent Psychiatry/ Psychotherapy at the University of
Ulm. Patients will be treated locally at the respective study
centers, with the exception of ADOPT Online, which will
be provided centrally online. Responsibility for the coordin-
ation of the whole ADOPT consortium and data manage-
ment is held by the Department of Child and Adolescent
Psychiatry, Psychosomatics and Psychotherapy, Medical
Faculty of the University of Cologne. Responsibility for mon-
itoring lies with the Clinical Trials Center Cologne. The
Institute of Medical Statistics and Computational Biology at
the University Hospital Cologne (IMSB) is responsible for
statistical analysis.
Inclusion and exclusion criteria
Participants will be included if they meet the following in-
clusion criteria: (i) child age: 8;0 to 12;11 years at T1; (ii)
child is resident with at least one natural parent/adoptive
parent (ADOPT Online/ADOPT Treatment) or (ii) child
lives in residential care/foster care (ADOPT Institution);
(iii) clinician-rated AD symptoms of the child (DADYS-PI)
based on parent interview > cut-off at T1 (ADOPT On-
line/ADOPT Institution)/T2 (ADOPT Treatment); (iv)
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willingness and ability of patient and parents/guardians to
participate in the intervention.
The following exclusion criteria will be applied and
evaluated at T1 (for ADOPT Treatment): (i) child’s
intelligence is below average based on clinical evalu-
ation/child attends school for children with intellectual
disabilities; (ii) mental disorder other than comorbid
conditions is the primary disorder and the main cause of
AD (e.g., autism spectrum disorder); (iii) current or
planned intensive behavioral therapy (ADOPT Online)/
psychotherapy (ADOPT Treatment and ADOPT Institu-
tion) or behavioral PMT on a weekly/biweekly basis.
In ADOPT Treatment and ADOPT Institution, thera-
pists administering THOPAS will have a university
degree in psychology or education and will be trained in
behavioral psychotherapy.
Allocation
Patients fulfilling the eligibility criteria at T1 will be cen-
trally registered and will be randomly assigned to the treat-
ment groups (ADOPT Online or TAU, allocation ratio 5:1;
THOPAS or TAU, allocation ratio 1:1) according to per-
muted blocks of varying length. Randomization will be
stratified by recruitment process (ADOPT Online and
ADOPT Treatment), gender and study site (i.e. 20 strata
altogether for ADOPT Online/ADOPT Treatment, 12
strata altogether for ADOPT Institution) and implemented
as a central 24–7 Internet service (ALEA, FormsVision BV,
Abcoude, NL) operated by local authorized study staff.
Treatment assignments will be displayed on screen and de-
livered by e-mail. The randomization service will be main-
tained by the IMSB, University of Cologne.
Interventions
ADOPT online
The material for ADOPT Online is based on an estab-
lished web-based ADHD parent-trainer [58], which is
adapted from evidence-based, print-based parent self-
help programs for reducing child externalizing behav-
ior problems [26, 32, 59]. The content and dosage of
the self-help programs have been evaluated previously
[29, 30, 60]. While the original version of the parent-
trainer focuses on changing the antecedents and
consequences of problem behavior and thus aims at
changing the behavioral component of AD, the modi-
fied online training combines these interventions with
aspects from the mindful parenting model and with
components from schema therapy.
The concept of effective parenting in the ADOPT Online
parent training combines parental control with positive at-
tention and support of the child’s emotion regulation to
strengthen the child’s self-efficacy. ADOPT Online provides
parents with access to three modules; the contents of these
modules are interconnected, and parents can work through
them in a flexible manner. In the first module (“Strengthen-
ing your child”), parents are instructed to support their
child to regulate aversive emotions using a 5-step plan that
involves mindfulness-based techniques to perceive and
identify feelings [61], taking a self-compassionate perspec-
tive [62], and using cognitive and behavioral strategies to
regulate emotions [63–65]. Additionally, the module leads
parents to analyze individual problems with their child
using videotaped examples (e.g., permanently bad mood,
outbursts of fury) in a step-by-step manner. Effective strat-
egies to change behavior problems are presented (e.g.,
ways to improve parent-child interactions, defining clear
rules, applying appropriate positive and negative conse-
quences) [66]. Parents are guided to use these strategies
on their child and to document the outcome. In the sec-
ond module (“Strengthening yourself”), parents are
instructed to apply the 5-step plan to their own emotions.
This module helps parents to deal with their own negative
emotions, which might occur as a reaction to the child’s
AD. Furthermore, parents are instructed to improve the
structures in their everyday life and to activate their own
resources. In line with schema therapy, parents are guided
to identify dysfunctional behavior that leads to strong
negative emotions [67, 68]. The third module (“Feelings:
Worth Knowing”) incorporates psychoeducation on AD
(e.g., AD as a disorder; the role of emotions; the develop-
ment of emotion regulation strategies) [63, 64, 69]. The
ADOPT Online training is illustrated with sketches and
short films to support social learning without direct ther-
apist contact.
We have chosen a three-month (= 12 weeks) duration for
ADOPT Online in order to provide sufficient time to
achieve a satisfactory degree of change for those parents
who use the material intensively [70]. Moreover, parents
who fail to use the material within this period of time are
unlikely to begin using it after 3months; for these parents,
and for children with residual AD symptoms, the next step
of the stepped care approach then needs to be addressed.
The entire material will be available from the begin-
ning of the three-month intervention period. During
this three-month period, participants will receive
reminders and reinforcement via automatically sent e-
mails. Information about the use of the online tool will
be collected from the system after participating par-
ents have provided informed consent. The online
material will be hosted by a professional service bound
to data safety and security by strict contracts that per-
mit only the study personnel to use any data produced
by the participants.
THOPAS
THOPAS consists of 10 CBT modules that include child-
based interventions, parent training interventions, and
teacher coaching. The 10 modules comprise interventions
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to activate resources and build a positive therapeutic rela-
tionship (module 1), interventions to strengthen positive
parent-child interactions (module 2) and to reduce
dysfunctional parenting (module 3), interventions to
strengthen positive teacher-child interactions (module 4)
and to reduce dysfunctional teacher behavior towards the
child (module 5), anger control training and training of
emotion regulation (module 6), empathy training (module
7), social problem solving and social skills training (mod-
ule 8), organizational skills training (module 9), and cop-
ing with trauma and negative life events (module 10).
In the parent-training and teacher-coaching modules
(2 to 5), target problems of the child are identified, along
with the child’s competencies and the coercive inter-
action process. The problem of maintaining social interac-
tions is addressed in the modification of social interactions
module, in which social rules are developed in order to
reduce the target problems of the child. This module in-
cludes how to communicate effective commands, how to
coach the child in social problem situations, methods for
rewarding the child (e.g., token systems) when the child
shows prosocial behavior, or appropriate methods of pun-
ishment (e.g., time-out) when the child shows aggressive
behavior. Additionally, these sessions aim at identifying and
modifying parents’ and teachers’ dysfunctional thoughts
about the child, as well as their own aggressive behavior,
impulse control, and conflict management.
The goals of the child-based interventions (modules 6
to 9) are to identify and reduce anger-inducing cogni-
tions (Anger thoughts) and basic dysfunctional ideas
(Thought traps; for example “I have to be better than
everyone”), and to develop empathy (Take another per-
son’s perspective). The anger control training addresses
impulse control (Control your anger), while the social
problem-solving and social skills training aims at helping
patients to develop and evaluate alternative solutions in
a problem situation, as well as to train them in skillful
non-verbal and verbal behavior, including role-play,
video feedback, and role-reversal. Organizational skills
training helps children to organize their daily tasks at
home and at school. In module 10, traumatic experi-
ences and negative life events are identified together
with the child; coping thoughts and a written narrative
are developed as the basis for a gradual exposure. The
child-centered interventions also include guidance for
parents/teachers to support the child’s behavioral change
at home/school.
The interventions in module 1 and modules 6 to 10
will be supported by a smartphone app which has been
developed for child psychotherapy. The app will be
installed onto the child’s smartphone or onto a therapy
smartphone that the child can take home to keep for the
duration of the therapy. With the help of the app, chil-
dren will be able to record therapy-relevant situations
and emotions and to transfer coping strategies from
therapy sessions to daily life. Self-management, thera-
peutic homework assignments, and interventions in the
real-life setting (Can you manage that in the real world?)
with self-reinforcement are added to each of these
modules.
The parent training interventions (modules 2 and 3)
are based on the evidence-based Treatment Program
for Hyperkinetic and Oppositional Problem Behavior
(THOP) [66], which is adapted from evidence-based
international treatment manuals, in particular Barkley’s
Defiant Children [71] and Helping the Non-compliant
Child [72]. The teacher coaching (modules 4 and 5) is
also based on the THOP program, as well as the newly
developed German-language School-based Coaching
for Teachers of Children with Disruptive Behavior
Problems (SCEP) [73], which is adapted from evidence-
based international treatment manuals, in particular
[74]. The child-centered interventions in modules 6–8 are
based on evidence-based German treatment programs – the
Treatment Program for Children with Aggressive Behavior
Problems (THAV) [75], and the Social Computer-assisted
Training for Children with Aggressive Behavior Problems
(ScouT) [47] – which are adapted from evidence-based inter-
national treatment manuals, in particular the Coping Power
Program [76] and the Cognitive-Behavioral Therapy for
Anger and Aggression in Children [46]. Module 9 is adapted
from the Organizational Skills Training for Children with
ADHDmanual [77]. Module 10 is adapted from Trauma-Fo-
cused Cognitive-Behavioral Therapy for Traumatized Chil-
dren (TF-CBT) [78].
The whole treatment encompasses a total of 24 sessions.
For each patient, a personalized treatment plan will be
developed by combining the treatment modules according to
the patient’s specific problems and problem-maintaining
factors, as assessed prior to treatment (by rating scales,
observational measures, and psychological tests). The indica-
tion for each module will be operationalized and the decision
for the personalized combination of the modules will be
documented. The CBT modules will be combined according
to the specific problems of the child (e.g. lack of problem-
solving skills or social skills, lack of anger control or emo-
tional regulation, lack of empathy, lack of organizational
skills, experience of traumatic events), the specific problem-
maintaining factors in the family (lack of parenting skills, lack
of positive parent-child interaction), or the specific problem-
maintaining factors at school (dysfunctional teacher-child in-
teractions, lack of positive teacher-child interaction). Clinical
decision-making flowcharts will be used, similar to those
developed in MATCH-ADTC [50] and the German treat-
ment programs THAV [75] and THOP [66]. In children with
severe ADHD, the clarification of an indication for psycho-
pharmacological treatment by an external physician will be
recommended. Whenever pharmacological treatment is
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recommended according to current treatment guidelines,
these interventions will be decided upon and fully carried
out by the clinical physicians of the respective participating
patient, independent from the study personnel.
Treatment as usual (TAU)
The control intervention includes TAU with an inter-
vention duration per patient of 12 (ADOPT Online) or
32 (ADOPT Treatment/ADOPT Institution) weeks. No
treatment condition is deemed unacceptable on ethical
grounds. TAU as control condition provides information
about the additional benefit compared to usual care. As
there is no gold standard in the treatment of AD, an ac-
tive treatment as a comparator is not feasible. Within
TAU, all psychosocial, psychotherapeutic and pharmaco-
logical interventions will be documented.
Concomitant care
Children with psychotropic medication and continued
symptoms of AD under medication at pre-treatment as-
sessment (T1/T2) will be included in the study. In
ADOPT Treatment and ADOPT Institution, children
with comorbid ADHD may be referred to a child and
adolescent psychiatrist to evaluate the indication for
additional pharmacological treatment. Decisions on pos-
sible pharmacological treatment will lie with the attend-
ing physician and will not be altered due to the study.
Documentation of pharmacological treatment will be
limited to the question (answered by the parents) of
whether the child is receiving any kind of psychotropic
medication and if so, for the treatment of which symp-
toms (ADHD/AD or other). Other intensive (behavioral)
psychotherapies or PMT (on a weekly/biweekly basis)
are not permitted in the experimental conditions.
Treatment fidelity
In ADOPT Online, there will be no therapist contact
with the participating parents. As the online intervention
will be the same for all participants, no strategies to
improve treatment fidelity are necessary. In ADOPT
Treatment and ADOPT Institution, treatment fidelity
will be assured by (i) training in manualized treatment
procedures, (ii) a structured protocol completed by ther-
apists after each session, and (iii) supervision of behavior
therapy by senior supervisors, either face to face or by
telephone. Behavior therapies will be supervised after
every four treatment sessions, including a review of at
least two videotaped sessions.
Participant timeline
For ADOPT Online and ADOPT Treatment, the individ-
ual study duration per patient is 19months. Measure-
ments will take place according to a specified schedule.
Immediately after the initial investigation (T0, screening),
the first measurement (T1) will occur, which involves an
examination of inclusion and exclusion criteria. For par-
ents of patients randomized to the experimental group at
T1, ADOPT Online will then be carried out over a period
of 12 weeks. Measurement T2 will take place 13 weeks
after T1. Families that were randomized to TAU after T1
will be offered ADOPT Online at T2. Non-responders to
ADOPT Online at T2 (significant symptoms of AD at T2
as rated by the clinician based on parent interview) will
subsequently be randomized to either THOPAS or TAU,
which will each be carried out over a period of 32 weeks.
T3 will occur 32 weeks after T2. The follow-up measure-
ment T4 will take place 32 weeks after T3. Thus, for all
patients in ADOPT Online, there will be four study visits
(T1-T4). For non-responders to ADOPT Online, who
continue treatment in ADOPT Treatment, there will be
24 additional study visits (24 behavior therapy sessions in-
cluding one intermediate measurement).
For ADOPT Institution, the individual study duration
per patient is 16 months. Measurements will take place
according to a specified schedule. Immediately after the
initial investigation (T0, screening), the first measure-
ment (T1) will occur, which involves an examination of
inclusion and exclusion criteria. Children with AD will
subsequently be randomized to either THOPAS or
TAU, which will each be carried out over a period of 32
weeks. T2 will take place 32 weeks after T1. The follow-
up measurement T4 will be conducted 32 weeks after
T2. Thus, for all patients in ADOPT Institution, there
will be three study visits (T1-T3). For children random-
ized to THOPAS, there will be 24 additional study visits
(24 behavior therapy sessions including 1 intermediate
measurement).
At the main assessment points (T1-T3/T4), the pri-
mary outcome (blinded clinician-rated AD symptoms
based on parent interview) and the secondary outcomes
will be assessed. In ADOPT Online, information about
the use of the online tool will be collected after partici-
pating parents have provided informed consent. The
intermediate assessments at T1b (ADOPT Institution)
and T2b (ADOPT Treatment) will only include parent-
and child-report questionnaires, and no clinical inter-
views. During T1b/T2b, potential treatment mediators
and predictors and short forms of the parent-rated AD
symptoms will be assessed. In addition, the therapist in
ADOPT Treatment/ADOPT Institution will complete a
questionnaire to measure adherence and treatment in-
tegrity at regular intervals during the treatment.
Informants
The following informants will be considered for assess-
ment: unblinded clinician, blinded clinician, parent/care-
giver, patient, and teacher.
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The unblinded clinician will be a member of the pro-
ject staff who is involved in diagnostics or in therapy
(but not in the family being assessed). He/she may be
aware of the treatment condition and the time of the as-
sessment, although efforts will be undertaken to blind
the raters. The blinded clinician will also be a member
of the project staff, and will be aware of neither the
treatment condition nor the time of the assessment. To
ensure blindness of the clinical rating of the primary
outcome, the parent interviews will be videotaped and
subsequently rated. Any information in the video mater-
ial that may disclose the treatment condition or the
measurement point (e.g., T1, T2, T3, T4) will be hidden
for the rating. The parent may be the biological parent
or the guardian of the child, and will be involved in the
treatment. The caregiver may be an educator in residen-
tial care or a foster parent. The patient is the child
participating in the study/treatment. The teacher is the
child’s schoolteacher, preferably the class teacher with
the main responsibility for the child’s school routine.
Outcomes
Primary outcome
The primary efficacy outcome is the blinded clinician-rated
AD symptom score of the child based on parent/caregiver
interview at T1-T4. To date, there is a lack of validated
measures on AD [6]. Therefore, the DADYS-PI will be
developed by another subproject of the ADOPT consor-
tium (ADOPT Epidemiology, in cooperation with ADOPT
Treatment) before the start of the trial, based on a pre-ver-
sion of DADYS-PI which will be psychometrically analyzed
in a clinical sample. The pre-version includes items based
on the Emotion Regulation Checklist (ERC) [79], the Diag-
nosis Checklist for Disruptive Behavior Disorder from the
German Diagnostic System for Mental Disorders in Chil-
dren and Adolescents (DISYPS-III) [80], the Affective Re-
activity Index (ARI) [81], the Parent Proxy Scale [82], and
the Pediatric Anger Scale from the Patient-Reported Out-
comes Measurement Information System [83].
Blinded clinician ratings based on parent/caregiver in-
terviews will be used as the primary outcome, since
these ratings should be less biased compared to parent
ratings and self-ratings of the child. The items of
DADYS-PI are scored from 0 (not present) to 3 (very
strong). These items are added up to a total score, repre-
senting the extent of AD symptoms of the child.
Secondary outcomes
The secondary endpoints are summary scores/scale
scores of the respective items. The secondary outcomes
listed below will be evaluated at T1-T4, unless otherwise
noted.
The secondary outcomes are (1) psychosocial impair-
ment of the child due to AD symptoms in blinded
clinical rating as well as patient, parent/caregiver, and
teacher rating, (2) patient-, parent/caregiver-, teacher-
and clinician-rated AD symptoms of the child, (3) pa-
tient-, parent/caregiver- and teacher-rated symptoms of
ADHD and ODD/CD, (4) other comorbid conditions
(e.g., anxiety, depression) assessed by parent/caregiver
ratings and teacher ratings, (5) psychological well-being
in patient and parent/caregiver rating, and (6) parent /
caregiver satisfaction with the treatment.
Psychosocial impairment of the patient due to AD
symptoms will be measured by the functional impair-
ment scale of the new version of the DISYPS-III [80].
The items are based on the definition of functional
impairment in DSM-5 and assess social impairment in
relationships with adults and other children, and impair-
ment in academic functioning. The reliability and valid-
ity of the scale have already been established in German
samples [80]. The items will be integrated into the clin-
ical interview (DADYS-PI) and into the questionnaires
for patient, parent/caregiver, and teacher rating (DADYS
questionnaires).
Patient-, parent/caregiver- and teacher-rated AD
symptoms of the child will be measured by newly devel-
oped questionnaires (DADYS questionnaires). Addition-
ally, there will be a clinical rating of AD symptoms of
the child based on a clinical interview with the child
(DADYS-CI). The instruments will be developed by an-
other subproject of the ADOPT consortium (ADOPT
Epidemiology, in cooperation with ADOPT Treatment)
before the start of the trial, based on a pre-version of the
DADYS questionnaires and DADYS interviews, which
will be psychometrically analyzed in a clinical sample.
The DADYS instruments include items based on the
ERC [79], FBB-SSV/SBB-SSV from the DISYPS-III [80],
ARI [81], the Parent Proxy Scale [82] and the PROMIS
Pediatric Anger Scale [83].
Comorbid symptoms of ADHD and ODD will be
assessed in patient and parent/caregiver rating using the
respective rating scales (Self-Rating Scale for ADHD,
SBB-ADHS; Self-Rating Scale for ODD and CD, SBB-
SSV; Rating Scale for ADHD, FBB-ADHS; Rating Scale
for ODD and CD, FBB-SSV) based on DSM-5 criteria
within the DISYPS-III [80]; reliability and validity as well
as sensitivity to change of these scales has already been
proven in German samples [80]. Teachers will rate co-
morbid symptoms of ADHD and ODD using selected
items of a screening questionnaire (Rating Scale for
Screening; FBB-Screen) of the DISYPS-III [80].
Further comorbidities will be assessed in parent/care-
giver and teacher rating with the German version of the
Child Behavior Checklist (CBCL/6-18R) [84] and the
Teacher Report Form (TRF/6-18R) [85]. Three subscales
will be used (Anxious/depressed, Attention problems,
Aggressive behavior).
Döpfner et al. BMC Psychiatry          (2019) 19:264 Page 11 of 20
Child symptoms of attachment disorders/posttrau-
matic stress disorders will be assessed in parent/care-
giver rating using the respective scales of the DISYPS-III
(Rating scale for attachment disorders, FBB-BIST; Rating
scale for trauma- and stress-related disorders, FBB-TBS)
based on DSM-5 criteria [80].
The KIDSCREEN questionnaires [86] measure subject-
ive health and well-being of children and adolescents as
rated by patients (KIDSCREEN-10-Index) and parents/
caregivers (KIDSCREEN-27).
For the assessment of satisfaction with the interventions
at T2 (ADOPT Online) or at T3 (ADOPT Treatment), spe-
cific parent/caregiver satisfaction rating scales have been
developed, based on the Client Satisfaction Questionnaire
(CSQ) [87].
Predictors/moderators of treatment outcome on AD
symptoms and impairment
As predictors/moderators of treatment outcome on AD
symptoms and impairment, the following variables will
be analyzed: (1) gender, (2) age of patients and parents/
foster parents, (3) recruitment process (community co-
hort vs. outpatient sample; in ADOPT Online/ADOPT
Treatment); (4) chronicity of AD symptoms, (5) severity
of AD symptoms, (6) severity of comorbid symptoms,
(7) AD symptoms and other psychopathology of the par-
ticipating parent/foster parent, (8) positive and negative
parenting practices, (9) receipt of social welfare assist-
ance by the family, (10) socioeconomic status of the
family/foster family, (11) early childhood neglect of the
patient, (12) adverse childhood experiences of the
patient, (13) family climate according to the child’s per-
ception, (14) social support and (15) personal resources
of the child. These parameters will be assessed at T1
and/or at T2. Additionally, (16) the profile of usage of
the online tool (ADOPT Online) as well as (17) the
implementation of treatment modules (ADOPT Treat-
ment/ADOPT Institution) will be assessed and analyzed
as predictors of treatment outcome in the intervention
groups, along with (18) treatment adherence and (19)
treatment fidelity in ADOPT Treatment/ADOPT Insti-
tution, both rated by the therapist, (20) the current
mood of the patient (measured with the momentary
assessment function of the therapy app), and (21) behav-
ior, thoughts, emotions, and reactions of the child in
therapy-relevant difficult situations (measured with the
video diary function of the therapy app).
Sociodemographic variables (e.g., gender of the patient,
age of patients and parents/foster parents, receipt of
social welfare assistance by the family/foster family, so-
cioeconomic status of the family/foster family) will be
assessed via parent/caregiver interview at T1.
The chronicity of AD symptoms of the child will be
assessed with the DADYS-PI (see above) at T1.
The severity of AD symptoms will be assessed at T2 in
blinded clinical rating as well as patient, parent/caregiver
and teacher rating using the DADYS-PI/questionnaires
(see above).
The severity of comorbid symptoms of the child will
be assessed at T2 using the SBB-ADHS/−SSV, FBB-
ADHS/−SSV, CBCL/6-18R, and TRF/6-18R (see above).
Additionally, at T1, comorbid symptoms will be assessed
in clinical rating, based on parent/caregiver interview
before treatment using a structured screening interview
which is part of the comprehensive Structured Interview
for Children and Adolescents according to ICD-10 and
DSM-5 from the DISYPS-III (DISYPS-III-ILF) [Görtz-
Dorten & Döpfner, in preparation]. ILF-SCREEN is a
semi-structured interview that is used to screen for core
symptoms of ADHD, ODD, anxiety disorders, depres-
sion, autism and problems with contact behavior in chil-
dren. For use in ADOPT Treatment, items concerning
developmental and excretion disorders will be excluded.
If ILF-SCREEN provides evidence of comorbid symp-
toms, additional scales from the DISYPS-III clinical
interviews, corresponding to these symptoms, will be
employed (ILF-External, ILF-Internal, ILF-Kontakt).
AD symptoms of the parent/foster parent participating
in the treatment of the child will be measured at T1 via
self-rating using the Aggression/Hostility subscale from
the German Brief Symptom Checklist (BSCL) [88]. The
scale consists of five items that are rated by the partici-
pating parent.
Psychopathology of parents and foster parents will be
assessed at T1 with the 9-item self-report short version
of the Symptom Checklist (SCL-K-9) [89].
Positive and negative parenting practices will be
assessed at T1-T4 via rating of the participating parent/
caregiver using the German Questionnaire for Positive
and Negative Parenting (FPNE) [90], which measures
positive parenting (e. g. reinforcing and supportive) and
negative parenting (e. g. harsh and inconsistent discipline).
Early childhood neglect and traumatic events of the pa-
tient will be assessed at T1 via parent/caregiver question-
naire using a modified version of the Symptom Checklist
for Attachment Disorders from the DISYPS-III [80] and
the Symptom Checklist for Posttraumatic Disorders from
the DISYPS-III [80].
Family climate will be assessed at T1 in parent/foster
parent rating using the Family Climate Scale [91].
Social support will be assessed at T1 in parent/care-
giver rating using the Social Support Scale (SSS) – Short
Version [92].
Personal resources of the child will be assessed with three
items from the Self-Efficacy Scale [93], one item from the
Bern Well-Being Questionnaire [94] and one item from the
Sense of Coherence Scale [95]. The items were modified for
the assessment in parent/caregiver rating.
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The profile of usage will be analyzed to identify the
frequency and duration of usage and the selection of
ADOPT Online modules.
Implementation of treatment modules, treatment adher-
ence and treatment fidelity will be rated by the therapists
in the THOPAS group after each session of treatment.
For the assessment of the child’s current mood using
the momentary assessment function of the therapy app,
the child will be asked to indicate how he/she is feeling
three times per day over three five-day periods (at the
beginning, in the middle and at the end of treatment).
Different basic emotions will be presented and the child
can choose between the emotions and indicate how
strong the emotion/s is/are perceived to be at the spe-
cific moment. Additionally, four items from the patient-
rated DADYS questionnaire (see above) will be included
in the momentary assessment function.
For the assessment of behavior, thoughts, emotions,
and reactions of the child in therapy-relevant difficult
situations using the video diary function of the therapy
app, the child will be asked to “tell” the app about a spe-
cific situation and to record it using the video function.
The child will then be asked to indicate the specific be-
havior, thoughts, emotions and reactions that occurred
in the situation.
Mediators of change
Potential mediators will be assessed at T1-T4 and at the
intermediate measurement T1b/T2b: (1) parent/care-
giver-reported positive and negative parenting practices
(measured with the FPNE, see above), and (2) use of
strategies to regulate affect and to reduce anger as re-
ported by the patient and the parent/caregiver. Addition-
ally, the child’s AD symptoms will also be assessed at
the intermediate measurements using patient- and par-
ent/caregiver-rated DADYS questionnaires (see above)
to determine whether changes in the potential mediators
preceded changes in outcome.
For the assessment of strategies to regulate affect and
reduce anger, as reported by the patient and the parent/
caregiver, we adapted the German questionnaire for the
assessment of emotion regulation (FEEL-KJ) [96]. The
questionnaire for patient rating was slightly modified
and enhanced. The items were then reworded for par-
ent/caregiver rating.
Strategies to regulate emotions of the child by the par-
ent/caregiver will be assessed in parent/caregiver report
with a modified version of the Coping with Children’s
Negative Emotions Scale (CCNES; German Version
VEEB) [97].
Sample size
In total, n = 597 children will be recruited for ADOPT
Online. The community sample will be drawn by ADOPT
Epidemiology. A screening tool for AD in children and cli-
nician’s rating in the outpatient sample will then be used
to identify the AD and the No AD sample. At T1, inclu-
sion and exclusion criteria will be evaluated for the AD
sample, resulting in an estimated sample size of n = 497
children, who will be randomized with an allocation rate
of 5 (ADOPT Online; n = 414) to 1 (TAU; n = 83).
In ADOPT Treatment, n = 232 children need to be
recruited and randomized with an allocation rate of 1
(THOPAS; n = 116) to 1 (TAU; n = 116). T3 assessment
needs to include n = 198 patients from the treatment
and control group (232 patients minus 34 lost at T3, i.e.,
20%). At T4, a total of n = 158 patients will be assessed
for further follow-up (assuming a further dropout of
20% from T3).
As the study designs of ADOPT Online and ADOPT
Treatment include a stepped care process, the sample size
is defined by the expected effect sizes of the ADOPT
Treatment step. The effect sizes found in the reported
meta-analyses of trials on the effects of mostly standard-
ized treatments in a group format (mostly compared with
waiting list control) are in the range of d = 0.3 to 0.6. The
effect sizes of personalized individual treatments tend to
be elevated, in the range of 0.6 to 0.8 [51, 98]. The planned
trial will be conducted with online treatment-refractory
AD and may therefore comprise a more severe group of
patients, who may be harder to treat. Thus, a moderate
effect size of d = 0.5 is expected. The two-sample t-test
with an allocation ratio of 1:1 (THOPAS: TAU) requires
64 patients per group in order to attain a power of 80% at
a two-sided significance level of 5%. A similar therapist
effect (due to clustering) as in [99] yields a design effect of
1.4 (intraclass correlation 0.1, five patients per therapist
on average); thus, n = 179 [128*1.4] patients are required
[100]. Further accounting for heterogeneous cluster sizes
(+ 10%) and attrition (+ 15%) yields approximately n = 232
patients to be randomized (n = 116 to THOPAS, n = 116
to TAU). Note that power is further increased by taking a
baseline-adjusted analysis of covariance (ANCOVA)/
mixed model for repeated measures (MMRM) approach
for statistical analysis. We expect a male:female ratio of 7:
3 [51]. Thus, the sample size of ADOPT Treatment is set
at n = 232, with n = 116 in the treatment arm and n = 116
in the control group.
Meta-analyses of self-help PMT report effect sizes be-
tween 0.61 and 1.01 [25, 27], with smaller effects for
self-help interventions with no therapist contact. It re-
mains unclear whether symptom severity serves as a
moderator favoring severely affected children in PMT
[22]. Breitenstein [27] reported mean completion rates
of about 78% in their meta-analysis on online PMT. In
studies on self-help PMT, dropout ranged between 5
and 30% [28, 56]. On the other hand, for highly bur-
dened parents, like those in our AD sample, online
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interventions might be harder to successfully complete.
Given this, and the fact that online PMT without therap-
ist contact is already less effective than telephone-
assisted self-help interventions, a small effect size such
as 0.378 should be expected for ADOPT Online. Thus,
the two-sample t-test with an allocation ratio of 5:1
(ADOPT Online: TAU) requires 331 and 66 patients,
respectively, to attain a power of 80% at a two-sided
significance level of 5%. Further accounting for 20%
attrition yields about n = 497 [≈ 397/0.8] patients to be
randomized (n = 414 to ADOPT Online, n = 83 to TAU).
Note that power is further increased by taking a base-
line-adjusted ANCOVA/MMRM approach for statistical
analysis. We expect a male:female ratio of 7:3 [51]. Miss-
ing data and non-compliance will be dealt with by per-
forming intention-to-treat (ITT) analysis.
In ADOPT Institution, a screening tool for AD in chil-
dren will then identify the AD (n = 166) and the No AD
(n = 80) sample in a total of n = 750 children in OHC.
According to the cut-off developed in ADOPT Epidemi-
ology, we expect that at least 25% of the screening sample
will be identified as screening-positive. Since the institu-
tions have already agreed to take part in the project, we
expect that most of the children screened positive will par-
ticipate in the intervention. A total of n = 166 children
need to be recruited and randomized with an allocation
rate of 1 (THOPAS) to 1 (TAU) (83 to the experimental
treatment, 83 to TAU). T2 assessment needs to be con-
ducted with n = 140 patients from the treatment and con-
trol group (166 patients minus 26 lost at T2, i.e., 20%) and
64 from the No AD group. At T4, a total of 169 patients
will be assessed for further follow-up (assuming a further
dropout of 20% from T2).
The planned trial will be conducted with children in
OHC, who presumably have a higher comorbidity load
and may therefore constitute a more severe group of
patients, who may be harder to treat. Thus, a moder-
ate effect size of d = 0.6 is expected. The two-sample t-
test with an allocation ratio of 1:1 (THOPAS:TAU)
requires 45 patients per group to attain a power of
80% at a two-sided significance level of 5%. A similar
therapist effect (due to clustering) as in [99] yields a
design effect of 1.4 (intraclass correlation 0.1, five
patients per therapist on average); thus, n = 126
[≈(45 + 45)*1.4] patients are required. Further ac-
counting for heterogeneous cluster sizes (+ 10%) and
attrition (+ 15%) yields about n = 166 [≈126/0.9/0.85]
patients to be randomized (n = 83 to THOPAS, n = 83
to TAU). Based on previous experience, we expect that
664 patients need to be screened for eligibility (i.e.
only 25% are eligible). Note that power is further in-
creased by taking a baseline-adjusted ANCOVA/
MMRM approach for statistical analysis. We expect a
male:female ratio of 7:3 [39].
Data management and confidentiality
ADOPT Coordination, in cooperation with the Clinical
Trials Center Cologne (CTCC), will provide electronic
questionnaires within the framework of a remote data
entry system (REDCap) [101] and will administer the
database. REDCap is a proprietary remote data entry sys-
tem which was developed by Vanderbilt University,
Nashville, TE, USA. An instance of REDCap is hosted
and maintained by the CTCC. Each investigator/data
entry personnel will receive separate access information
for the use of the REDCap system. An audit trail within
REDCap provides a data history of which data were
entered, changed or deleted, when and by whom. The
data will be reviewed for completeness, consistency and
plausibility. Data corrections will be entered directly into
REDCap by the responsible investigator or a designated
person.
Details of the data management (procedures, responsi-
bilities, timelines, data validation and data corrections)
will be described in a data management manual (DMM)
prior to trial start. The DMM is a working document
that is adapted during the clinical trial and contains a
record of all data management processes carried out.
Each patient will receive a consecutive patient identifi-
cation number (ID) after screening. The ID will be
entered in the centralized database (REDCap) for the
registration of the patient.
For ADOPT Institution, the ID will be assigned by the
person who completes the screening questionnaire (i.e.,
the caregiver) with instructions provided by ADOPT
Institution. Thus, screening can be performed without
disclosure of identifying information of the child in the
study center. After identification of a screening-positive
case and after informed consent of the guardians has
been obtained, the child and caregiver will be invited for
T1 assessment and further participation in ADOPT
Institution.
ADOPT Coordination, in cooperation with the CTCC
and the PIs, will process data through personnel who are
specifically trained for the study, and who will then work
in accordance with the standard operating procedures
(SOPs) of the study centers. Legal regulations for data
protection will be fulfilled.
Statistical analysis
Patient demographics/other baseline characteristics
Demographic and other baseline data (including disease
characteristics) will be obtained at T1 and will be sum-
marized descriptively using all documented patients.
Continuous data will be summarized by arithmetic
mean, standard deviation, minimum, 25% quantile, me-
dian, 75% quantile, maximum, and the number of
complete and missing observations. If appropriate, con-
tinuous variables can also be presented in categories.
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Categorical data will be summarized by the total num-
ber of patients in each category and the number of miss-
ing values. Relative frequencies will be displayed as valid
% (number of patients divided by the number of patients
with non-missing values).
Analysis of primary endpoint
The primary (full) analysis set is derived from the ITT
principle (all patients randomized with a valid baseline
assessment: ADOPT Online/ADOPT Institution: T1/
ADOPT Treatment: T2 and at least one follow-up meas-
urement). The primary outcome measures “change in
AD symptoms from T1 to 13 weeks post-randomization
(T2)” (ADOPT Online), “change in AD symptoms from
T2 to 32 weeks post-randomization (T3)” (ADOPT
Treatment) and “change in AD symptoms from T1 to 32
weeks post-randomization (T2)” (ADOPT Institution)
will be evaluated by an ANCOVA, with fixed effects
baseline, study center, gender and treatment arm and
corresponding marginal means and contrast tests (type
II sums of squares). Interactions of study center and
gender with treatment arm will be explored. Data from
study centers with low recruitment (i.e., < 10 patients)
will be pooled. The potential clustering of observations
of participants by therapist or center will be investigated
using multilevel modelling. Multiple imputation ap-
proaches will be taken to assess the robustness of the
results. Specifically, missing values will be separately im-
puted by type assuming mixtures of missingness-not-at-
random patterns [102]. Imputation data sets will be
post-processed by multiplication with factors and
addition of offsets (tipping point analysis) [103]. Proxy
measures will be taken into account to ameliorate the ef-
fects of attrition.
Analysis of secondary endpoints
Secondary outcomes (i.e., further time points and mea-
sures) will be analyzed along the same lines, possibly
using MMRM (heterogeneous first-order autoregressive-
structured covariance matrix over time) or generalized
estimating equation approaches with corresponding
marginal means and contrast tests (“multilevel model-
ling”). Time-to-dropout distributions will be summarized
by the Kaplan-Meier method and compared using the
(stratified) log-rank test. Adverse events will be aggre-
gated by type, seriousness, intensity and relatedness. All
efficacy and safety variables will be summarized by time
point and treatment arm (mean, standard deviation, per-
centiles (i.e., minimum, 25th, 50th, 75th, and maximum),
count, percentage). Subgroup analyses will be conducted
according to recruitment process, study center and gender
(expected male to female ratio of 7:3, thus, meaningful
results are expected for boys and girls). Moreover, moder-
ation, mediation and conditional process modelling [104]
will be conducted based on regression and structural
equations (interaction, simple slope analysis; direct/indir-
ect effects, kappa square). All of the details, particularly
regarding how to deal with missing data and attrition, will
be documented in a statistical analysis plan.
Missing values
It should be emphasized that as few patients as pos-
sible should discontinue treatment and that all pa-
tients should be followed up and also documented
after discontinuation of the treatment in order to rec-
ord data required according to the ITT principle. To
assess the impact of up to 20% attrition, multiple im-
putation approaches will be taken, accounting for
proxy measures and assuming specific missingness-
not-at-random patterns. The details will be docu-
mented in a statistical analysis plan. Analysis of
subjects essentially observed and treated per protocol
is supportive.
Safety
Safety analyses will be performed in the safety popula-
tion. Patients in the safety population will be analyzed
as belonging to the treatment arm defined by treatment
received (ADOPT Online or TAU; ADOPT Treatment/
ADOPT Institution: THOPAS or TAU). Patients will
be included in the respective treatment arm if treat-
ment was started/if they received at least one dose of
trial treatment. Patients who refuse participation in
ADOPT Online/THOPAS will also be part of the safety
population.
Data monitoring
Data monitoring committee
A Data Monitoring Committee (DMC) has been
established. The DMC comprises three experts with
expertise in conducting clinical trials and specific ex-
pertise in biostatistics, psychotherapy, and child and
adolescent psychiatry. Prior to the implementation of
the trials, a DMC charter will be worked out, de-
scribing goals and the work plan of the board. The
DMC will assess, on an annual basis, whether the
execution of the study is still ethically justified and
whether performance is acceptable.
Harms
In the framework of the study, the evaluation of toler-
ability/safety will be restricted to the occurrence of
serious adverse events (SAEs). An SAE is defined as an
event that: (1) results in the participant’s death, (2) is a
suicide attempt; (3) results in hospitalization for non-
suicidal self-harm; or (4) results in hospitalization for
mental health problems. All serious adverse events will
be reported to the independent DMC.
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Auditing
Monitoring will be performed by the CTCC in cooper-
ation with the ADOPT Coordination subproject. All
investigators agree that the monitor is allowed to visit
the center before and during the study. The pre-study
monitoring visit and all other monitoring visits will be
performed by the CTCC in accordance with the trial
protocol, the established quality management system
(SOPs), and guidelines of the International Conference
on Harmonization of Good Clinical Practice (ICH-GCP).
The results of the pre-study visits will be documented
and reported back to the funding agency. The monitor-
ing strategy will be specified within a study-specific
monitor manual.
Stopping rules
Stopping rules for an individual patient
One (or more) of the following circumstances will result
in an early study termination of single subjects (these
trial subjects will be rated as dropouts): (i) withdrawal of
informed consent of all parents/guardians; (ii) with-
drawal of assent of the patient; (iii) unwillingness to fur-
ther participate in the trial; (iv) need for inpatient
treatment or other reasons affecting the patient’s well-
being in the case of continued trial participation; (v)
need for a different kind of treatment for health reasons
according to the judgment of the attending physician.
Global stopping rules
A termination of the entire consortium will be executed
if both ADOPT Epidemiology and ADOPT Institution
fail to reach 50% of the planned sample size, despite
additional recruitment strategies. The decision will be
made by all principal investigators as well as the princi-
pal coordinator.
Discussion
The ADOPT study will inform about the benefits of
online self-help for parents and intensive personalized
modular treatments compared to standard approaches.
These effects will be related to AD symptoms, comorbid
symptoms, functional impairment, and psychological
well-being. The study will also inform about putative
predictors, moderators and mediators of intervention
effects on AD. The modular approach will have a strong
impact on clinical practice, as it will help clinicians to
adapt their treatment to the needs of the individual
patient. For children living in OHC, especially effects on
functional impairment and quality of life, but also effects
on multiple placements or early discontinuation of youth
welfare interventions, will be of high relevance for the
individual child, but also of economic relevance for the
health care and youth welfare system.
The results will have a large impact on clinical prac-
tice, as they will (1) improve assessment of the clinical
condition (also in a high-risk population of children
living in OHC), (2) inform about the relation of AD and
clinical diagnoses of co-existing disorders and about risk
and protective factors, (3) introduce personalized modu-
lar psychological transdiagnostic treatment and increase
treatment effects. Since AD is an important risk factor
for the development of severe mental disorders, the
results should affect the health status of the pediatric
target population in later periods of life. Therefore, the
results of the proposed project will be highly relevant for
the assessment and treatment of children with AD and
comorbid conditions.
The results of the ADOPT study will inform future
guidelines on the treatment of children with AD and
comorbid conditions and will help to improve guidelines
and to develop usable, potentially more cost-effective,
individualized modular treatment in children with AD in
the mental health care system and youth welfare system.
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